Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03693040|
Recruitment Status : Recruiting
First Posted : October 2, 2018
Last Update Posted : October 2, 2018
This study uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new Proteus Digital Health (PDH) technologies approved by the FDA, to collect information about patients taking their Pre-Exposure Prophylaxis (PrEP) medication for HIV prevention. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which gives healthcare providers information about when patients have taken their PrEP medication.
The purpose of the study is to demonstrate that the DHFS is easy to use and acceptable to people taking PrEP; that patients will persist with its use; and that the system provides valid, accurate measures of adherence.
|Condition or disease||Intervention/treatment||Phase|
|HIV Prevention||Device: Digital Health Feedback System||Not Applicable|
This study is a prospective single arm open label intervention study over 12 weeks using the DHFS with participants initiating or continuing HIV PrEP. The study intervention has an initiation (Phase 1), persistence (Phase 2) and follow-up period up to 96 weeks. In phase 1 participants will use the DHFS with close follow-up incorporating visits with directly observed ingestions. In Phase 2 the participants utilize the DHFS in their natural setting with sporadic study visits until 12 weeks. Eligible HIV seronegative participants will receive an ingestible sensor enabled oral antiretroviral (IS-ARV) of TDF/FTC (Truvada®). The study will be conducted at the UCSD AVRC. Participants will be recruited from UCSD AVRC, UCSD Owen Clinic, related or affiliated UCSD primary care programs or community primary care clinics. Following the 12 week intervention participants will undergo HIV testing and continuation on HIV PrEP and followed for up to 96 weeks. The primary outcome will be an accurate measure of adherence i.e. the number of doses of selected IS-ARVs ingested, as captured by the DHFS, over the number of doses prescribed, adjusted for positive detection accuracy (PDA), defined as the percentage of detected sensors that have been administered under direct observation.The investigators will also assess the acceptability and feasibility of longitudinal monitoring in real time of the ingestion rate utilizing the DHFS. In addition the investigators will evaluate the ability of the DHFS to identify participants whose longitudinal medication taking and timing patterns in the first 12 weeks of ARV treatment puts them at risk for HIV infection as far out as 96 weeks from start of treatment.
• To obtain TDF/FTC serum levels data comparing co-encapsulated IS-Truvada formulation to native Truvada® as supplemental information to dissolution studies.
A subset of 12 participants prescribed IS-Truvada®:(tenofovir disoproxil fumarate/emtiritabine) for PrEP will be enrolled in a PK sub-study to provide supplementary data to dissolution studies conducted by Gilead Sciences on the co-encapsulated IS-Truvada formulation. On Day 14 of treatment, when drug concentrations are expected to be close to steady state, sub-study participants will have a PK profile for Tenofovir and Emtricitabine obtained over a single dosing interval (at time 0 (pre-dose Ctrough), 2, 4, 6, 8 and 24 hours). Participants will be seen at the AVRC in a fasting state prior to taking their dose of IS-Truvada® and will remain fasting for 2 hours after the observed ingestion. The time and date of the previous doses of IS-Truvada® will be recorded by and available from the DHFS prior to initiating the PK procedures. The following day, Day 15, the participant will return to the AVRC in a fasting state. The 24 hour plasma sample will be drawn. Participants will then receive an observed dose of native Truvada. Participants will remain fasting for 2 hours after the observed ingestion and will have plasma samples drawn at 2, and 4 hours after ingestion.
Samples will be analyzed for tenofovir and emtricitabine drug concentration levels either individually or in batches at the central specialized laboratory.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)|
|Actual Study Start Date :||December 1, 2016|
|Estimated Primary Completion Date :||December 31, 2018|
|Estimated Study Completion Date :||December 31, 2018|
Experimental: DHFS with IS-Truvada
Digital Health Feedback System (DHFS) with IS-Truvada 1 capsule daily for 12 weeks
Device: Digital Health Feedback System
This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
- Medication Taking Adherence [ Time Frame: 12 weeks ]Medication taking adherence, defined as the number of doses ingested as captured by the DHFS over the number of doses prescribed, adjusted for Positive Detection Accuracy ( determined by the percentage of PrEP medication ingestion detected by the DHFS administered under witnessed observation).
- The system positive detection accuracy (PDA) will be derived [ Time Frame: 12 weeks ]2. PDA is determined by the percentage of HIV PrEP ingestion detected by the DHFS administered under witnessed observation, overall for all study subjects. PDA will be based upon proper DHFS use. The PDA will be calculated for a single tablet regimen.
- Determine the percentage of participants starting or continuing HIV PrEP who find the DHFS acceptable and easy to use. [ Time Frame: 12 weeks ]Acceptability and participant satisfaction with the DHFS will be accessed based on the self-report DHFS User Experience questionnaires which include open ended questions and a detailed DHFS User Experience questionnaire with Likert scale covering overall assessment, ease of use, time needed to use the system, perceived personal benefit and negative impressions.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03693040
|Contact: Sara H Browne, MD. MPH||858 email@example.com|
|Contact: Amanda J Tucker Maytom, MD||619 543 firstname.lastname@example.org|
|United States, California|
|UCSD AntiViral Research Center||Recruiting|
|San Diego, California, United States, 92103|
|Contact: Sara H Browne, MD MPH 858-822-6563 email@example.com|
|Contact: Amanda J Tucker Maytom, MD 6195433145 firstname.lastname@example.org|
|Study Chair:||Sara H Browne, MD MPH||UCSD AntiViral Research Center|
|Study Chair:||Constance A Benson, MD||UCSD AntiViral Research Center|